Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer

Sponsor
Sichuan Provincial People's Hospital
Study ID
NCT02998242
Status
Completed

Conditions

  • Quality of Life

Eligibility Criteria

Sex
MALE
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
  • SBRT to symptomatic bony metastatic bony site(s) — RADIATION

Study Details

To study safety and efficacy of apatinib in combination of radiotherapy in patients with symptomatic bony disease prostate cancer (SBPC), based on the potential synergistic antitumor activity between Apatinib and Stereotactic Body Radiation Therapy (SBRT).

Key Dates

Start date
May 10, 2016
Status verified
May 2019
Primary completion
Jan 5, 2017
Completion
Dec 10, 2017

Study Design

Enrollment
40 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: RT alone
    symptomatic bony metastatic site(s) receive SBRT less than 5 fractions
  • Experimental: RT with apatinib
    selected dose administered PO during and after SBRT

Primary Outcome Measure

biochemical disease free survival [ Time Frame: 2 years ]

Related Studies